De-escalated Teclistamab dosing in relapsed/refractory multiple
myeloma: Czech myeloma group real-world evidence analysis

J 2025

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis

ŠTORK, Martin; Jakub RADOCHA; Jana MIHALYOVA; Ivan SPICKA; Tomas PIKA et al.

Základní údaje

Originální název

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis

Autoři

Vydání

Annals of hematology, New York, Springer Verlag, 2025, 0939-5555

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30205 Hematology

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.400 v roce 2024

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/25:00143747

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Multiple myeloma; Teclistamab; Immunotherapy; Real-world-evidence

Štítky

14110212, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 24. 2. 2026 10:22, Mgr. Tereza Miškechová

Anotace

V originále

Teclistamab, a BCMAxCD3 bispecific antibody, demonstrates high efficacy in relapsed/refractory multiple myeloma (RRMM). However, optimal dosing strategies outside clinical trials remain undefined. Thus, we performed a retrospective, multicentre analysis of 73 RRMM patients treated with teclistamab monotherapy at Czech Myeloma Group centres between 2023 and 2025. The study compared efficacy and safety between patients receiving standard weekly dosing and those with reduced-frequency dosing. The whole cohort had a median age of 67 years; 68.5% were penta-refractory. Dosing was de-escalated in 24.7% of patients, typically within one month of treatment initiation. Median progression-free survival (PFS) was 9.41 months and was comparable between weekly and non-weekly groups (9.1 vs. 11.3 months; p = 0.141), despite a significantly lower relative dose intensity in the latter (60.5% vs. 87.0%; p < 0.001). Infection rates and severe adverse events were similar between groups. A lower incidence of neutropenia was observed with less frequent dosing, but this did not translate into reduced infection burden. In conclusion, in real-world practice, early de-escalation of teclistamab dosing appears to maintain clinical efficacy. These findings support ongoing efforts to individualize treatment schedules with the aim of balancing effectiveness, tolerability, and patient-specific factors in BCMA-targeted therapy.

Citovat

ŠTORK, Martin; Jakub RADOCHA; Jana MIHALYOVA; Ivan SPICKA; Tomas PIKA; Alexandra JUNGOVA; Ivanna BOICHUK; Klára MENŠÍKOVÁ; Jan STRAUB; Frantisek SEDLAK; Jiri MINARIK; Petra KRHOVSKA; Denisa NOVAKOVA; Michaela HORNAKOVA; Zdeňka KNECHTOVÁ; Nela SENDLEROVÁ; Tereza DEKOJOVA; Vladimir MAISNAR; Tomas JELINEK; Roman HAJEK a Luděk POUR. De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis. Annals of hematology. New York: Springer Verlag, 2025, roč. 104, č. 8, s. 4141-4147. ISSN 0939-5555. Dostupné z: https://doi.org/10.1007/s00277-025-06529-1.

@article{2556396,
   author = {Štork, Martin and Radocha, Jakub and Mihalyova, Jana and Spicka, Ivan and Pika, Tomas and Jungova, Alexandra and Boichuk, Ivanna and Menšíková, Klára and Straub, Jan and Sedlak, Frantisek and Minarik, Jiri and Krhovska, Petra and Novakova, Denisa and Hornakova, Michaela and Knechtová, Zdeňka and Sendlerová, Nela and Dekojova, Tereza and Maisnar, Vladimir and Jelinek, Tomas and Hajek, Roman and Pour, Luděk},
   article_location = {New York},
   article_number = {8},
   doi = {https://doi.org/10.1007/s00277-025-06529-1},
   keywords = {Multiple myeloma; Teclistamab; Immunotherapy; Real-world-evidence},
   language = {eng},
   issn = {0939-5555},
   journal = {Annals of hematology},
   title = {De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis},
   url = {https://link.springer.com/article/10.1007/s00277-025-06529-1},
   volume = {104},
   year = {2025}
}

TY  - JOUR
ID  - 2556396
AU  - Štork, Martin - Radocha, Jakub - Mihalyova, Jana - Spicka, Ivan - Pika, Tomas - Jungova, Alexandra - Boichuk, Ivanna - Menšíková, Klára - Straub, Jan - Sedlak, Frantisek - Minarik, Jiri - Krhovska, Petra - Novakova, Denisa - Hornakova, Michaela - Knechtová, Zdeňka - Sendlerová, Nela - Dekojova, Tereza - Maisnar, Vladimir - Jelinek, Tomas - Hajek, Roman - Pour, Luděk
PY  - 2025
TI  - De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis
JF  - Annals of hematology
VL  - 104
IS  - 8
SP  - 4141-4147
EP  - 4141-4147
PB  - Springer Verlag
SN  - 09395555
KW  - Multiple myeloma
KW  - Teclistamab
KW  - Immunotherapy
KW  - Real-world-evidence
UR  - https://link.springer.com/article/10.1007/s00277-025-06529-1
N2  - Teclistamab, a BCMAxCD3 bispecific antibody, demonstrates high efficacy in relapsed/refractory multiple myeloma (RRMM). However, optimal dosing strategies outside clinical trials remain undefined. Thus, we performed a retrospective, multicentre analysis of 73 RRMM patients treated with teclistamab monotherapy at Czech Myeloma Group centres between 2023 and 2025. The study compared efficacy and safety between patients receiving standard weekly dosing and those with reduced-frequency dosing. The whole cohort had a median age of 67 years; 68.5% were penta-refractory. Dosing was de-escalated in 24.7% of patients, typically within one month of treatment initiation. Median progression-free survival (PFS) was 9.41 months and was comparable between weekly and non-weekly groups (9.1 vs. 11.3 months; p = 0.141), despite a significantly lower relative dose intensity in the latter (60.5% vs. 87.0%; p < 0.001). Infection rates and severe adverse events were similar between groups. A lower incidence of neutropenia was observed with less frequent dosing, but this did not translate into reduced infection burden. In conclusion, in real-world practice, early de-escalation of teclistamab dosing appears to maintain clinical efficacy. These findings support ongoing efforts to individualize treatment schedules with the aim of balancing effectiveness, tolerability, and patient-specific factors in BCMA-targeted therapy.
ER  -

ŠTORK, Martin; Jakub RADOCHA; Jana MIHALYOVA; Ivan SPICKA; Tomas PIKA; Alexandra JUNGOVA; Ivanna BOICHUK; Klára MENŠÍKOVÁ; Jan STRAUB; Frantisek SEDLAK; Jiri MINARIK; Petra KRHOVSKA; Denisa NOVAKOVA; Michaela HORNAKOVA; Zdeňka KNECHTOVÁ; Nela SENDLEROVÁ; Tereza DEKOJOVA; Vladimir MAISNAR; Tomas JELINEK; Roman HAJEK a Luděk POUR. De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis. \textit{Annals of hematology}. New York: Springer Verlag, 2025, roč.~104, č.~8, s.~4141-4147. ISSN~0939-5555. Dostupné z: https://doi.org/10.1007/s00277-025-06529-1.

Přehled o publikaci